Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis

Marilynn Larkin  |  

“Weight-bearing exercise is good for anyone who is physically able to do so,” he added. “Our population was patients who were put on teriparatide after experiencing a fragility fracture. Many of these patients still are able to do some weight-bearing exercises but to a lesser extent than you or I.”

Dr. Jeffrey A. Goldstein, director of the spine fellowship program at NYU Langone Health in New York City, told Reuters Health by email, “The findings are supported by the research, and reiterate the benefits of teriparatide as well as the need to follow teriparatide with antiresorptive medications.”

ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Burkard D, Beckett T, Kourtjian E, et al. Effects of bone remodeling agents following teriparatide treatment. Osteoporosis International. 2018 Mar 14. [Epub ahead of print]

Related Articles

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…